Member Info for AquaeSulis01

Yes , Friedman. Cut my losses when I sold at 11.5p back in June after realising the Dr Morepen forecasts were a pipedream and H&B appear to be dropping the their SlimExpert Range (no products currently stocked).

Another 2,000,000 shares sold by Opti to keep the lights on over there

Shychap, it doesn't matter what slant you put on the vote all that counts is how the market interprets the votes for:

https://www.investegate.co.uk/announcement/rns/skinbiotherapeutics--sbtx/result-of-agm/9322868

SkinBioTherapeutics plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the re-appointment of auditors and director remuneration. Key resolutions regarding the allotment of securities for cash, both generally and for acquisitions, also received significant backing, with votes for ranging from 80.84% to 81.34%, indicating shareholder confidence in the company's strategic financial flexibility.

https://www.tipranks.com/news/company-announcements/skinbiotherapeutics-wins-shareholder-backing-for-growth-and-capital-authorities-at-agm

You may as well make your trip to Newcasle worthwhile rather than a complete waste of time shychap by booking yourself in for the New Year and relieving some of that stress. https://new.newcastle.gov.uk/news/2025/howaymanay-very-newcastle-new-years-eve-celebration

Toyin, SA made it very plain that he would only put out the most pessimistic forecast in future to avoid the reaction he got when SBTX missed last years target; so worst case scenario £6.2M and £0.7M Adj EBITDA, not too shabby for a growth Company with a Market cap of just £34M, especially when compared to Belgrano's previous tip of Insig-ai, M/C £27M ,£0.3M cash prior to a further £1m fund raise and H1 revenue of just £438k.

Regarding Dermatonic's revenue contribution, a large element of their miss would have been down to Umesh Modi I suspect, it will be interesting to see what the ROW contribution is when the Interims are produced.

· Two new vertical markets entered, with two new customer wins post period end

· Cash at period end of £0.03 million (H1-24 £0.23 million)

· £1 million new equity raised at 30.5p per share post period end

Did not anticipate contributing anything further to the BB this Calendar Year and then a correction RNS arrives; happy days.

Regarding the Singer “Market” Revenue Forecasts of £5.1M 2025 (223% uplift), £6.2M 2026 (22%) and £8.2M 2027 (32%) worth noting the following:

The 223% revenue uplift based on £5.1M was from the H/Y 2025 actual revenue of £1,576,531 rather than the end FY 2024 revenue figure of £1,208,669, the Actual revenue uplift based on the lower revenue achieved on only £4.6M was a higher 284%.

A 22% revenue uplift for 2026 on a revised lower 2025 baseline figure of £4.6M would give a forecast of £5.6M, so in essence by retaining the 2026 original forecast the predictions are for a 34% rather than a 22% rise next year and hence why no change has been made to the revenue figure I guess, even though Toyin makes a compelling case as to why it could be higher.

Must admit was taken aback this morning when I received a second invitation to vote at the AGM having previously voted in favour of all agenda items; I will be abstaining second time around.

Personally, I doubt very much that a major shareholder(s) has informed SA they intend to vote against Directors being re-elected but I can envisage them abstaining from the vote at this juncture until the claimed progress in the Interim Results can be verified. Further disappointment when those results are known may well then trigger one or more large shareholders to call an EGM at that point.

Anyway, irrespective of whether TW can organise the 5% he needs to call one in advance of the Interims or not, I suspect by the time an EGM is requisitioned and the Board respond to it and then set a date, the Interims will be out so either way I am going to relax and enjoy my Christmas and New Year; seasons greetings extended to all here

no idea you had been banned. thought the mention of people being banned by lemmings was more to do with leaking info to ************* where tw appears to be on a personal vendetta against sa rather than focusing his efforts on calling out frauds. could be wrong there as i have cancelled my subscription to ************* following recent rants.

Our

Toyin, chill, this has been aired to death, are feelings replayed to the Board and now time to look forward Not back and hope lessons learnt. Shychap we have never had £5.9M non croda revenue forecasts for 2025 it was £5.3M ex croda and poi t made to SA by elric during the recent q & a

Appreciate that toyin bit if the orders received post integration and dealt with at lower cost are late so will the realised befits be late

Toyin you appear to be confusing integration with synergies. The integration of the Companies have completed ( benefits delivered) and the synergies are now being realised ( benefits realisation)

Shychap, it is the profit margin in the Singer note that tells you there is no Croda revenue included in the 2025 forecast.

Shychap, I think Singer have little option other than to upgrade their 2026 and beyond forecasts for the simple reason their Croda revenue expectations are running a year ahead of schedule as they had nothing in for 2025 so at the very least I would expect their 2026 forecasts to reflect their current 2027 forecasts of £8.2M rather than £6.2M

What we do know is that millions of pounds worth of ingredient has been purchased and it hasn't been purchased in those volumes to sit in a lab storeroom. not sure about you shychap, but if I was running a Business I would have been trialling the ingredient in my products using the samples and only ordering in volume if I was intending to launch. As regards marketing, think we can leave that safely in the hands of the multi-nationals

Shychap "But while the Croda FY25 royalties estimate is higher than many expected, we should probably wait to see how re-orders from Croda's customers pan out before getting over-excited. It's a new product and not even SBTX know enough about Croda's sales yet to predict what will happen in 2026 and beyond. Hopefully we will learn more over the next 12 months." not sure shareholders are focused on whether there will be reorders at the current rate rather than how quicky sales ramp up to twice/three times/etc the current order rate; in other words when will the first products hit the streets.

I attach for any new investors the Croda presentation used at the launch and there is one thought experiment that can be carried out now. Ask friends, and relatives of all ages whether a new world first ingredient that triggers the release of melatonin to help you get a restful sleep and also kids your brain to believe your biological clock is younger than it actually is so that it increases the release of collagen 1 by 36% and collagen IV by 67% and in so doing improves the elasticity of the skin, and see what reaction you get; I suspect it will be where and how soon can I buy it?

P.s. Some snake-oil Nige

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.skinbiotherapeutics.com/wp-content/uploads/2025/04/Croda-Beauty-Actives_Technical-seminar-theatre-4_8th.pdf

And just for the record for those that don't access Lemmings, Elric said nothing about a third acquisition or limiting to functional cosmetics, those are my own thoughts

Yes just read it PG , it is an excellent piece and I stand corrected; in theory sbtx could certainly make their own brand cosmetics containing zenakine, in practise, may well be they choose not to do so for the reasons highlighted by Elric. Unless they acquire a third Company with Beauty skin care products suitable for incorporating zenakine in, I also suspect if SBTX elects to enter the Cosmetic market it may well be restricted to incorporating zenakine into functional cosmetics such as the over the counter Dermatonic's Manuka Honey heel balm to further enhance its properties. Thank you Elric fir tge clarification.

Having slept on this one the language used in 2022 appears more of a negotiating tactic to move things along as the launch of symbiotic was taking longer than expected and so sbtx were talking of making it themselves using the formula as well. Also, zenakine has proved to have far more active properties than first envisaged hence the Swiss Army Knife descriptive. Consequently I am struggling to think of a cosmetic you could put zenakine in that would not make the product an active cosmetic and certainly not out own face mask. AI definition "An active skincare cosmetic is defined by the presence of ingredients that directly improve or treat skin conditions, while a non‑active cosmetic only supports the formulation and user experience without delivering targeted results. Both are essential: actives provide the benefits, and inactives make the product safe, stable, and pleasant to use."

Now contrast this with the wording my that appeared in say 2022 half year results RNS rather than th wording in the Nov 2024 Final Agreement RNS "The Sederma agreement is limited to consumer 'active skincare' and therefore, SkinBioTherapeutics is able to develop its own line of cosmetic-related SkinBiotix products, based on Sederma's formulation, and continues to explore this opportunity."